Revolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial Evaluating Zoldonrasib in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Patients with Metastati
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall St set to open lower after AI-led selloff; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude hits more than five-month high on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| (NASDAQ: RVMD) | Delayed: 185.09 -2.6 (1.39%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $187.69 | 52 Week High | $ | |||
| Open | $187.59 | 52 Week Low | $ | |||
| Day High | $187.78 | P/E | N/A | |||
| Day Low | $183.80 | EPS | $ | |||
| Volume | 67,761 | |||||
